STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Rhea-AI Summary
Merck and Eisai provide update on Phase 3 trial for KEYTRUDA and LENVIMA combination in head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
clinical trial
-
News

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Rhea-AI Summary
LYNPARZA combination approved in Japan for BRCA-mutated castration-resistant prostate cancer with distant metastasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
-
News

Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

Rhea-AI Summary
WELIREG shows positive Phase 3 results in RCC trial with statistically significant improvements in PFS and ORR compared to everolimus. OS results inconclusive. Safety profile consistent with previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
clinical trial
News

Merck Employee Talks Pride, Pediatrics and Parenting

Rhea-AI Summary
Merck & Co., Inc. - Dr. Rodney Finalle, a pediatrician and global director of medical affairs, shares his personal journey as a member of the LGBTQ+ community and the support he received from his workplace and community. Merck's partnership with a program matching professionals with nonprofit boards allowed Finalle to join the board of a local LGBTQ+ community center.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
none
-
News

Merck Is Harnessing Innovation To Reach Indigenous Communities

Rhea-AI Summary
Merck & Co., Inc. - Alaska partners with University of Alaska and drone provider to demonstrate drone delivery of medicines to remote villages, showcasing innovative solutions for increasing access to lifesaving pharmaceuticals in extreme weather and terrain. The project aims to expand access to medicines in remote areas, addressing the challenges faced by people living in Alaska's 240 remote villages and communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
News

Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

Rhea-AI Summary
Anixa Biosciences, Inc. (ANIX) announces the enrollment of subjects in a treatment arm evaluating the combination of its breast cancer vaccine with Keytruda (pembrolizumab) by its partner, Cleveland Clinic. The trial aims to determine if the vaccine/Keytruda combination increases immune response against triple negative breast cancer (TNBC), with potential synergistic effects. The company looks forward to the presentation of updated data from this trial at the San Antonio Breast Cancer Symposium in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
clinical trial
News

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

Rhea-AI Summary
Merck (NYSE: MRK) has received FDA approval for the expanded indication of ERVEBO, a vaccine to prevent Zaire ebolavirus disease in individuals 12 months and older. The vaccine was previously approved for those 18 and older. The European Medicines Agency's Committee also recommended expanded approval for individuals 1 year and older. ERVEBO has a contraindication for individuals with a history of severe allergic reactions to any component of the vaccine. The vaccine's effectiveness when administered with other medications is unknown. Merck has also confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags
fda approval
-
News

Merck Announces Second-Quarter 2023 Financial Results

Rhea-AI Summary
Merck reports Q2 2023 financial results with total worldwide sales of $15.0 billion, an increase of 3% from Q2 2022. Key highlights include growth in KEYTRUDA and GARDASIL sales, decline in LAGEVRIO sales, and a GAAP loss per share of $2.35.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
earnings
-
News

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

Rhea-AI Summary
Merck (MRK) announces positive Phase 3 study results for KEYTRUDA in combination with chemotherapy for high-risk, early-stage ER-positive, HER2-negative breast cancer, showing a significant improvement in pCR rate compared to neoadjuvant placebo plus chemotherapy. The trial will continue to evaluate the other primary endpoint of event-free survival. Safety profile consistent with previous studies. Results to be presented at upcoming medical meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
clinical trial
News

Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Rhea-AI Summary
Merck (NYSE: MRK) Announces Positive Phase 3 Results for V116 Pneumococcal Vaccine, Demonstrating Strong Immune Responses in Adults
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
clinical trial

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.62 as of November 26, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 254.7B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#35 Ranked by Market Cap
#946 Ranked by Dividends

MRK Stock Data

254.66B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH